Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
pharmaceutical investing Immune Design Receives Orphan Drug Designation for G100 Intratumoral Product Candidate
Sun Summit Commences Drilling and Provides Exploration Update from the JD Project in BC's Toodoggone District
